2013-2016: Not losing momentum

Since the financial crisis of 2008 and more recently the end of the Millennium Development Goals, funding for HIV treatment and prevention programmes provided by the international community has contracted. Though big players, like the Global Fund, still invest substantial amounts, the trend to stop funding projects in middle-income countries threatens the progress that has been made against the HIV epidemic.

It is hoped that setting ambitious new international targets will keep up the pressure on world leaders to tackle HIV. UNAIDS’ Fast-Track strategy and 90/90/90 targets aim to greatly step up the HIV response in low- and middle-income countries.

The goal of ending the HIV epidemic by 2030 is achievable if the political will is there.

PopART study primary results

Primary results from the largest community-randomised trial of the universal HIV test-and-treat strategy find that treatment alone is unlikely to end the epidemic.

International Guidelines on Human Rights and Drug Policy

A new set of international legal standards are released to reshape the response to the world drug problem.

HIV self-testing – evidence update

After recommending self-testing as an effective way to reach more people with HIV, the WHO issues an updated policy brief to optimise its implementation.

Climate change and HIV

Increasing evidence emerges about the impact of climate change on the HIV epidemic.

WHO recommends dolutegravir (DTG) as preferred HIV treatment

Based on new evidence, the WHO recommends DTG as the preferred first-line and second-line treatment for all populations, including pregnant women.

ECHO trial results

The ECHO trial finds no increased HIV risk in HIV-negative women using Depo-Provera compared to other contraceptives.

PARTNER2 study confirms U=U message

PARTNER2 trial results confirm that gay men can also benefit from U=U.

DREAMS initiative

The DREAMS initiative is established to reduce HIV infections among adolescent girls and young women in sub-Saharan Africa.

Dolutegravir (DTG) and women’s right to choose

DTG debate brings into question women’s power to make decisions about their reproductive health.

Pages

Subscribe to RSS - 2013-2016: Not losing momentum